Title :

Irisin levels in lmna-associated partial lipodystrophies

Author(s) :

Bensmaine, F. [Auteur]
Benomar, Kanza [Auteur]
Stephanie, Espiard [Auteur]
Service Endocrinologie, diabétologie, maladies métaboliques et nutrition [LILLE - Endocrino]
Vahe, C. [Auteur]
Le Mapihan, K. [Auteur]
Lion, Georges [Auteur]
Lemdani, Mohamed [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
221576|||Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS] (VALID)
Chazard, Emmanuel [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Ernst, Olivier [Auteur]
Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189
489340|||Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI] (VALID)
Vigouroux, C. [Auteur]
Pigny, Pascal [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Vantyghem, Marie-Christine [Auteur]

Recherche translationnelle sur le diabète (RTD) - U1190

Journal title :

Diabetes & Metabolism

Abbreviated title :

Diabetes Metab.

Volume number :

45

Pages :

67-75

Publisher :

Elsevier Masson

Publication date :

2018-08-27

ISSN :

1262-3636

English keyword(s) :

Lamin A
Irisin
Lean mass
Leptin
Fat mass
Lipodystrophy

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The adipo-myokine irisin regulates energy expenditure and fat metabolism. LMNA-associated familial partial lipodystrophy (FPLD2) comprises insulin resistance, muscle hypertrophy and lipoatrophy. The aim of this study was ...
Show more >The adipo-myokine irisin regulates energy expenditure and fat metabolism. LMNA-associated familial partial lipodystrophy (FPLD2) comprises insulin resistance, muscle hypertrophy and lipoatrophy. The aim of this study was to investigate whether irisin could be a biomarker of FPLD2. This case control study included 19 FPLD2 subjects, 13 obese non-diabetic (OND) patients and 19 healthy controls (HC) of normal weight (median BMI: 26, 39 and 22 kg/m2 BMI and MRI intra-abdominal fat significantly differed among these three groups, whereas DXA total fat mass and leptin levels were higher in the OND group, but did not differ between HC and FPLD2. Lipodystrophy patients had higher intra-abdominal/total abdominal fat ratios than the other two groups. Irisin levels were higher in FPLD2 and OND patients than in HC (medians: 944, 934 and 804 ng/mL, respectively). However, irisin/leptin ratios and lean body mass percentages were strikingly higher, and lean mass indices lower, in FPLD2 and HC than in the OND (median irisin/leptin ratios: 137, 166 and 21, respectively). In the entire study group, irisin levels positively correlated with BMI, lean body mass and index, intra-abdominal/total abdominal fat ratio, triglyceride, cholesterol, insulin, glucose and HbA1c Circulating irisin is similarly increased in FPLD2 and OND patients, who are characterized by higher lean body mass regardless of their clearly different fat mass. However, irisin/leptin ratios, strikingly higher in FPLD2 than in OND patients, could help to make the diagnosis and prompt genetic testing in clinically atypical cases.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Thérapies Lasers Assistées par l'Image pour l'Oncologie (ONCO-THAI) - U1189

Submission date :

2019-12-09T18:20:37Z
2021-06-25T08:32:41Z
2024-04-03T08:10:00Z